ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Cladribine Tablets Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland
March 26, 2019Merck KGaA, Darmstadt, Germany, a leading science and technology company…… -
Up to 10-years of follow-up data reaffirm safety profile of Mavenclad (cladribine tablets)
October 12, 2018Merck, the vibrant science and technology company, today announced the presentation of new data for MAVENCLAD® (cladribine tablets) at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) in Berlin, German -
Cladribine Tablets receives positive CHMP opinion for treatment of relapsing forms of MS
June 27, 2017Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical trials.
Pharma Sources Insight January 2025
